Ben Franklin Technology Partners of Southeastern Pennsylvania

Ben Franklin Technology Partners of Southeastern Pennsylvania is a non-profit organization established in 1982 that focuses on fostering the development and adoption of new technologies in the region. For over 30 years, it has served as a key provider of seed-stage capital, investing more than $170 million in over 1,750 regional technology companies, many of which have achieved industry leadership. In addition to financial support, Ben Franklin promotes university and industry partnerships that facilitate the commercialization of scientific discoveries. The organization is dedicated to strengthening the entrepreneurial ecosystem in Southeastern Pennsylvania, thereby creating jobs and enhancing the technology community.

Jason Bannon

Vice President of Marketing and Communications

Jonathon Beschen

Managing Director

Patrick J. Foley

Former Member of Physical Sciences Investment Advisory Committee

Elaine Fulton

Receptionist & Operations Assistant

Richard E. Genzer

Investor

Mark de Grandpre

Investor

Jennifer Hartt

Managing Director

John A. Loftus

Director

Tristan Ly

Director of Portfolio Administration

Adare Mcmillan

Chief Administrative Officer and Assistant Treasurer

OMAR G. MENCIN, DBA

Managing Director

Douglas R. Petillo

Member of Information Technology Investment Advisory Committee

Aston Pierce

Investor

Charles M. Robins

Director

Stephen Spinelli

Director

Kate Srinivasan

Client Engagement Manager

Mark S. Trabbold

Director of Business Development

Past deals in Maryland

Houwzer

Seed Round in 2017
Houwzer, LLC provides real estate brokerage services for buying and selling a home. It also provides industry insights for home buyers and sellers. In addition, it offers communication tools, featured listings, total transaction management, social and email marketing, and direct mail campaign services. The company was incorporated in 2014 and is based in Philadelphia, Pennsylvania with additional offices in Washington, District of Columbia; Baltimore, Maryland; and Haddonfield, New Jersey.

Corridor Pharmaceuticals

Series A in 2010
Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.